CareDx Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high-value, non-invasive surveillance solutions for transplant recipients, announced new evidence that the proportion of cell-free DNA (cfDNA) derived from the transplanted organ and found in the bloodstream of the recipient is correlated to the rejection status of the organ. This new biomarker (cfDNA) in combination with AlloMap, the company's molecular diagnostic surveillance solution, provides greater accuracy of identification of rejection in heart transplant recipients than either test alone.
